An interventional study of Adapted ESTEEM intervention in Stigma, Social, sponsored by Yale University. Completed at 1 site in United States. Open to male participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by Yale University · Not applicable, Interventional, and Prevention
Among 92 studies in Social Stigma with a site in United States — 19 open to participants now, 25 under way, none of them phase 3. Social Stigma · United States.
Among the 92 studies in Social Stigma with a site in United States, this one is the 76th largest by enrollment of the 82 interventional ones that give a count, is one of 4 that started in 2025, is one of 77 with no phase, and was the 90th registered.
266 studies on the registry are indexed under Social Stigma; 66 are open to participants now.
Browse Social Stigma studies →19 of the 92 studies in Social Stigma with a site in United States are open now. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in United States
Ages 8+
University of Washington · Sites in United States
Ages 18+ · Healthy volunteers
VA Office of Research and Development · Sites in United States
Ages 18+
George Mason University · Sites in United States
Ages 18+ · Healthy volunteers
Illinois Institute of Technology · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 34 Social Stigma studies recruiting now, 25 (74%) set no upper age limit and 8 (24%) stop at 75 or younger; 4 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 35 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2025.
This study's enrollment of 20 is below the median of 139 across 217 interventional studies indexed under Social Stigma.
Median enrollment 120 across the 82 interventional studies, 327 across the 10 observational. Of the 61 that completed or were terminated, 16 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 92 have an industry lead sponsor. The 10 most frequent:
Yale University is the lead sponsor of 1,770 studies on the registry; 294 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
Yale University has 4 studies filed under Social Stigma — fewer than ten, so there is no comparison to draw.
11 of the studies in Social Stigma with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05174936University of South CarolinaResIlience-based Stigma REdUction Program ("Rise-up") | 2026-11-30 |
| NCT05436106Emory UniversityBehavioral Intervention to Reduce Stress Among Black Gender Minority Women | 2026-12 |
| NCT07594730New York State Psychiatric InstituteBrief Intervention Addressing Stigma Among Parents of Children With Mental Health Problems | 2026-12-01 |
| NCT07545577George Mason UniversityRandomized Controlld Trial of Dementia Education Resources for Action | 2026-12-30 |
| NCT06316804Massachusetts General HospitalMobile Mental Health Stigma Reduction Intervention Among Black Adults | 2027-01-01 |
Among the 92 studies in Social Stigma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This open pilot involves testing the acceptability and feasibility of an intersectional, culturally responsive health intervention by piloting it among young Black and Latino/x gay, bisexual, and queer (GBQ+) men residing in Middle Tennessee. Qualitative exit interviews will be conducted to provide information regarding intervention feasibility, acceptability, and refinement; changes in primary and secondary study outcomes will help assess efficacy potential. Effective Skills to Empower Effective Men (ESTEEM), has been shown to decrease negative mental health symptomology and HIV risk behavior among a racially diverse sample of young GBQ+ men. This study would inform the cultural adaptation of ESTEEM to fit the unique and intersectional experiences of Black and Latino/x GBQ+ men living in the South, and in particular within Middle TN. The adaptation and group pilot stands to significantly improve stigma coping and the mental/sexual health of Black and Latino/x GBQ+ men in Middle TN-and in turn impact the HIV burden in the Southern US.
These research activities seek to further the reach and cultural-appropriateness of a clinically effective evidence-based intervention (ESTEEM) by further adapting ESTEEM-conneCT (a group-based treatment designed for gay and bisexual men of color in Fair Haven, CT) for young Black and Latino/x GBM residing in Middle Tennessee. The intervention study will take place in Nashville, TN with a partnership between the Nashville CARES and the Yale School of Public Health (YSPH). This pilot will guide further refinement, identify facilitators and barriers to scaling up, and yield effect size estimates for powering future studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive the adapted ESTEEM intervention over 11 sessions
Behavioral: Adapted ESTEEM intervention
culturally-responsive behavioral health intervention
Center for Epidemiological Studies-Depression Scale (CES-D) score
The CES-D is a 20-item measure that assesses frequency of past-week depression symptoms (e.g., "I was bothered by things that usually don't bother me") on a 4-point scale from 0 (rarely or none of the time \[less than 1 day\]) to 3 (most or all of the time \[5-7 days\]). The item scores are summed, with higher scores indicating greater risk for clinical depression. Total score range 0-80.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Overall Depression Severity and Impairment Scale (ODSIS) score
ODSIS is a 5-item self-report scale that asks participants to rate the severity and impairment associated with past-week symptoms of depression (e.g., "In the past week, when you have felt depressed, how intense or severe was your depression?") from 0 (little or none: Depression was absent or barely noticeable.) to 4 (extreme: Depression was overwhelming.). The item scores are summed, with higher scores indicating greater severity and impairment. Total score range 0-20.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Overall Anxiety Severity and Impairment Scale (OASIS) score
OASIS is a 5-item self-report scale that asks participants to rate the severity and impairment associated with past-week anxiety symptoms (e.g., "In the past week, when you have felt anxious, how intense or severe was your anxiety?") from 0 (little or none: Anxiety was absent or barely noticeable.) to 4 (extreme: Anxiety was overwhelming. It was impossible to relax at all. Physical symptoms were unbearable). The item scores are summed, with higher scores indicating greater severity and impairment. Total score range 0-20.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Brief Symptom Inventory (BSI) score
The 18-item BSI provides a mean score across depression, anxiety, and somatization subscales, and assesses psychological distress (e.g., "feeling nervousness or shakiness inside") on a 5-point scale from 0 (not at all) to 4 (extremely). The item scores are summed with higher scores indicating greater severity and impairment. Total score range 0-72.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Suicidal Ideation Attributes Scale (SIDAS) score
SIDAS is a 5-item self-report scale that assesses past-month frequency and controllability of suicidal thoughts, how close one has come to making an attempt, and distress and impairment associated with thoughts of suicide (e.g., "In the past month, how often have you had thoughts about suicide?"). Responses range from 0 (never or not at all) to 10 (always or extremely). The item scores are summed, with higher scores indicating greater severity of suicidal ideation. Total score range 0-50.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Short Inventory of Problems - Alcohol and Drugs (SIP-AD) score
SIP-AD is a 15-item scale in which the sum of "yes" responses indicates participants' past-3-month consequences of alcohol and drug use (e.g., "I have failed to do what is expected of me because of my drinking/drug use?). The item scores are summed, with higher scores indicating greater problems related to drugs and alcohol. Total score range 0-15.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Mean Recent HIV-risk Acts
Mean Number of Recent HIV-risk Acts self reported using the timeline follow-back method
Time frame: Baseline (0-30 days before the start of the trial) and post-intervention (three months after the trial)
Psychological Health Change
The number of the mental health variables that change in the expected direction. The eight psychological health variables include: depressive symptoms; anxiety; social anxiety; suicidal ideation; psychological distress; substance use problems; rumination; and assertiveness.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Sexual Health Change
The number of sexual health variables that change in the expected direction. The four sexual health variables include: Recent HIV transmission risk acts; condom use self-efficacy; sexual compulsivity; and recent PrEP use.
Time frame: Baseline (0-30 days before the start of the trial) and post-intervention (three months after the trial)
Social Interaction Anxiety Scale score
A 20-item self-report scale that assesses fear, distress, and anxiety a person feels during general social interactions. Responses range from 0 (Not at all characteristic of me) to 4 (Extremely characteristic of me). The item scores are summed, with higher scores indicating greater level of social anxiety. Total score range 0-80.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Mean score Ruminative Responses Scale - Brooding Subscale
The Brooding Subscale is a 5-item measure that assesses maladaptive cognitive patterns when feeling down, sad, or depressed (e.g., "Think 'why do I always react this way?'") on a 4-point scale from 1 (Almost Never) to 4 (Almost Always). The item scores are averaged, with higher scores indicating greater ruminative brooding. Total score range 0-4.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Rathus Assertiveness Schedule score
The Rathus Assertiveness Schedule is a 30-item measure that assesses assertiveness and passivity (e.g., "I often have a hard time saying 'No.'") on a 6-point scale from +3 (very characteristic of me) to -3 (very uncharacteristic of me). The item scores are summed, with positive scores indicating higher assertiveness and negative scores indicating lower assertiveness or passivity. Total score range 90 to -90.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Alcohol Use Disorders Identification Test (AUDIT) score
The AUDIT assesses past-3-month alcohol and related problems across 10 items (e.g., "How often did you have a drink containing alcohol?") with varying numeric response options (0-4). The item scores are summed, with higher scores indicating greater alcohol-related risk. Total score range 0-40.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Mean score Safer Sex Self-Efficacy Questionnaire
Condom use self-efficacy will be measured by calculating mean scores on the Safer Sex Self-Efficacy Questionnaire. The Safer Sex Self-Efficacy Questionnaire is a 13-item measure that assesses confidence in avoiding having anal sex without a condom in different situations (e.g., "When you are with someone who is really hot?") on a 5-point scale from 1 (Not at all confident) to 5 (Extremely confident). The item scores are averaged, with higher scores indicating greater condom use self-efficacy. Total score range 1-13.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Sexual Compulsivity Scale score
The Sexual Compulsivity Scale is a 10-item measure that assesses difficulties regulating sexual desire (e.g., "I think about sex more than I would like to") on a 4-point scale from 1 (Not at all lke me) to 4 (Very much like m). The item scores are summed, with higher scores indicating greater Sexual Compulsivity. Total score range 10-40.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Percent participants with recent PrEP use
Recent PrEP use will be measured by calculating proportions of participants who reported any PrEP use over the past 3 months. Three types of PrEP were described before participants were asked, "Which methods of PrEP (Pre-Exposure Prophylaxis) administration have you used to reduce the risk of getting HIV over the past 3 months? Select all that apply." Answer options included Daily PrEP (i.e., 4-7 days a week), On-demand PrEP (i.e., the "2-1-1" schedule), Injectable PrEP (i.e., every two months), and I have not taken PrEP in any form over the past three months.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Stigma Coping Strategies
Number of protective strategies that increased and risk-enhancing strategies that decreased.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Stigma Coping- Adaptiveness Scale score
Coping response will be scored on a 5-point adaptiveness scale (created for this study) ranging from 1 (Definitely adaptive \[or almost certainly so\]) to 5 (Definitely maladaptive \[or almost certainly so\]) with higher scores indicating worse coping. Total score range 1-5.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Internalized Homophobia Scale score
The Internalized Homophobia Scale is a 9-item measure that assesses internalized homophobia on a 4-point scale from 1 (Never) to 4 (Often). The item scores are summed, with higher scores indicating greater internalized homophobia. Total score range 9-36.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Gay-Related Rejection Sensitivity Scale score
The Gay-Related Rejection Sensitivity Scale is a 14-item measure that the likelihood of expecting rejection by heterosexuals in more or less ambiguous situations with answers on a scale ranging from 1 to 6 with higher scores indicating greater rejection. Total score range 1-6.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Mean Outness Inventory (OI) score
The OI is an 11-item scale designed to assess the degree to which lesbian, gay, bisexual, and queer individuals are open about their sexual orientation. Responses on OI items indicate the degree to which the respondent's sexual orientation is known by and openly discussed with various types of individuals on a 7-point scale from 1 (person definitely does NOT know about your sexual orientation status) to 7 (person definitely knows about your sexual orientation status, and it is OPENLY talked about); if the person of group is not relevant to them, participants select 0 (not applicable to your situation; there is no such person or group of people in your life). The item scores are averaged, with higher scores indicating greater sexual orientation disclosure. Total score range 0-4.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Mean Sexual Orientation Concealment Scale (SOCS) score
This version of the Self-Concealment Scale is a 6-item measure that assesses sexual ), a brief self-report measure assessing effort to conceal one's sexual identity in one's current life (e.g., "In the last 2 weeks, I have altered my appearance, mannerisms, or activities in an attempt to 'pass' as straight.") on a 5-point scale from 1 (Not at all) to 5 (All the time). The item scores are averaged, with higher scores indicating greater concealment. Total score range 1-5.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Internalized Racism score
Internalized racism will be measured as mean of participant scores on a 5-item measure that assesses negative thoughts and beliefs about one's own racial minority status. Participants were presented with a question regarding their racial/ethnic identity (e.g., "How do you feel today about being a person of your racial/ethnic background?"), which they answer by completing five semantic differential scales, each ranging from 1 (a negative characteristic) to 5 (a corresponding positive characteristic): uncomfortable to comfortable, dissatisfied to satisfied, ashamed to proud, strong to weak, and self-accepting to self-rejecting. The item scores are summed, with higher scores indicating greater internalized racism. Total score range 5-25.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Mean Racism-Related Vigilance scale score
The scale is a 7-item measure includes four items that assess (a) racial/ethnic vigilance (e.g., "try to prepare for possible insults from other people before leaving home") on a 4-point scale from 0 (Rarely) to 3 (Almost every day), total score range 0-3.and (b) race-related sleep disturbance over the past four weeks (e.g., waking very early with trouble getting back to sleep) on a 5-point scale from 1 (At least once a week) to 5 (Never), total score range 1-5. The item scores are averaged, with higher scores indicating greater race-related vigilance.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Anticipatory Race-Related Stress Subscale of the Prolonged Activation and Anticipatory Race-Related Stress Scale score
The Anticipatory Race-Related Stress Subscale is a 4-item measure that assesses race-related anticipatory stress on a 7-point scale from 1 (Not at all stressful) to 7 (Extremely Stressful). The item scores are averaged, with higher scores indicating greater race-related anticipatory stress. Total score range 1-7.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Heterosexism & Cissexism in Communities of Color Subscale of the LGBTQ+ PCMS-R score
This is a 6-item subscale measure that assesses perceived heterosexism within one's racial/ethnic community on a 7-point scale from 0 (Not applicable) to 6 (Always). Then, participants are presented with directions reading, "Imagining if you were to experience ongoing anti-LGBTQ stigma within your racial/ethnic community, such as:" and all six subscale items were presented. They are then asked, "If you were to encounter situations like these..." before encountering three follow-up questions to assess distress (e.g., "to what extent would the situation stress or bother you?"). The initial subscale score is multiplied by the stress score to compute stress related to heterosexism in one's racial/ethnic community, with higher scores indicating greater intracommunity heterosexism. Total score range 0-30.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Racism within LGBTQ+ Communities Subscale of the LGBTQ+ PCMS-R score
This is a 6-item subscale measure that assesses perceived racism in the White LGBTQ+ community (e.g., "I have felt misunderstood by White LGBTQ+ people because I am a POC.") on a 5-point scale from 1 (To a little extent) to 5 (To a great extent). Then, participants are presented with directions reading, "Imagining if you were to experience ongoing racism within the LGBTQ+ community, such as:" and all six subscale items were presented. They are then asked, "If you were to encounter situations like these..." before encountering three follow-up questions to assess distress (e.g., "to what extent would the situation stress or bother you?"). The initial subscale score is multiplied by the stress score to compute stress related to heterosexism in one's racial/ethnic community, with higher scores indicating greater intracommunity heterosexism. Total score range 0-30.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Conflicts in Allegiances Scale score
The Conflicts in Allegiances Scale is a 6-item subscale measure that assesses conflicts between the racial/ethnic and sexual orientation identities they endorsed previously within the survey (e.g., "I separate my \[insert sexual orientation\] and \[insert racial/ethnic group\] identities.") on a 7-point scale from 1 (Disagree strongly) to 7 (Agree strongly). The item scores are averaged, with higher scores indicating greater identity conflict. Total score range 1-7.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Queer People of Color Identity Affirmation Scale score
This is a 12-item measure that assesses identity affirmation among LGBTQ+ people of color on a 7-point scale from 1 (Very strongly disagree) to 7 (Very strongly agree). The item scores are averaged, with higher scores indicating greater Southern LGBTQ-POC identity strength. Total score range 1-7.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Queer and Trans Black, Indigenous, and People of Color (QT-BIPOC) Resilience Measure score
This is a 20-item subscale measure that assesses the ways oppression has shaped their individuals and community QT-BIPOC resilience on a 7-point scale from 1 (Strongly Disagree) to 7 (Strongly Agree). The item scores are averaged, with higher scores indicating greater intersectional stigma resilience. Total score range 1-7.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Stigma-Related Stress Change
Number of the mental health variables that change in the expected direction out of the 13 psychological health variables.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)
Perseverative Cognition Subscale Subscale of the Prolonged Activation and Anticipatory Race-Related Stress Scale score
The Perseverative Cognition Subscale Subscale is a 5-item measure that assesses race-related rumination on a 7-point scale from 1 (Not at all stressful) to 7 (Extremely stressful). The item scores are averaged, with higher scores indicating greater race-related anticipatory stress. Total score range 1-7.
Time frame: Baseline (0-14 days before the start of the trial) and post-intervention (three months after the trial)]
Plan to share: Yes — De-identified qualitative and quantitative IPD will be preserved and shared with qualified researchers upon request.
No publications or documents are linked to this record.
Ran from Apr 2025 to primary completion in Nov 2025, 7 months.
Of 162 non-industry interventional studies with no phase under Social Stigma, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 7 months is below that.
Counting every sponsor, half of 164 studies reached it within 15 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.